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a  b  s  t r  a  c  t
Members  of the  type  III interferon  gene  family  arose  by gene  duplication  events  and  have  retained  a high
percent  identity  both  in  their  coding  and  non-coding  regions.  In  this  study,  the  speciﬁcity  of  a  widely
used  TaqMan® SNP genotyping  assay  for rs12979860  is validated.  The  66 bp template  for  SNP  genotyp-
ing  has  only  3 bp  at one  5′ end  that vary  between  IL-28B  and  IL-28A;  excluding  the  rs12979860  SNP
itself.  Conﬂicting  annealing  temperatures  were  found  for the  mismatched  19  bp  primer  to IL-28B  and  IL-
28A  with  in  silico  melting  temperature  algorithms,  or  with  in  vitro dissociation  curves.  In order  to prove
speciﬁcity  for  IL-28B,  an  in  vitro  competition  assay  was  setup  with  genomic  DNA  and  synthetic  oligonu-
cleotides.  When  genomic  DNA,  containing  equimolar  concentrations  of  rs12979860  and  the  homologous
region  of  IL-28A  are  present,  no off-target  ampliﬁcation  was observed.  This SNP  genotyping  assay  is
therefore  speciﬁc  for rs12979860  and  all previously  reported  results  are  valid.  Finally,  using  a  completely
synthetic  in  vitro  competition  assay  it was  possible  to calculate  the  amount  of  off-target  template  thatff-target ampliﬁcation will  produce  1/2  the  maximum  on-target  (VIC)  ﬂuorescent  signal,  a value  that  is between  a C/C genotype
and  a T/T  genotype.  This  value  is  deﬁned  in the  manuscript  as  the  half  maximum  positive  value,  KHPV,
and  in the  present  assay  KHPV is  15.75  ± 0.0721,  represented  as  the  relative  fold  increase  in the  amount
of  IL-28A  over  rs12979860.  This  method  will  be of  interest  to those  performing  genotyping  on  highly
conserved  gene  families.
ublis© 2014  The  Authors.  P
. Introduction
Hepatitis C virus (HCV) is the cause of signiﬁcant disease burden
orldwide, and is manifested by liver ﬁbrosis, cirrhosis, and hepa-
ocellular carcinoma. In North America, HCV is the leading indicator
or liver transplantation. Until the recent addition of protease
nhibitors, the treatment of HCV was pegylated interferon and riba-
irin, which had varying efﬁcacy depending on both the viral and
ost genotypes. For patients infected by HCV genotype 1, interferon
nd ribavirin treatment is only 50% efﬁcacious (Feld and Hoofnagle,
005; Fried et al., 2002; Hadziyannis and Koskinas, 2004; Kamal
t al., 2007; Manns et al., 2001; Moghaddam et al., 2011). Genome
ide association studies identiﬁed two non-synonymous single
ucleotide polymorphisms (SNP) upstream of the IL-28B gene that
orrelated with response to treatment with IFN/ribavirin or spon-
aneous viral clearance (Ge et al., 2009; Suppiah et al., 2009; Tanaka
∗ Corresponding author. Tel.: +1 780 492 9819; fax: +1 780 492 5304.
∗∗ Corresponding author. Tel.: +1 780 492 8415; fax: +1 780 492 5304.
E-mail addresses: brad.s.thomas@gmail.com, brad.thomas@ualberta.ca
B.S. Thomas), lorne.tyrrell@ualberta.ca (D.L.J. Tyrrell).
ttp://dx.doi.org/10.1016/j.jviromet.2014.03.016
166-0934/© 2014 The Authors. Published by Elsevier B.V. This is an open access article uhed  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/3.0/).
et al., 2009; Thomas et al., 2009). IL-28B is a member of the type III
interferons, which are known to inhibit viruses such as HCV (Doyle
et al., 2006; Robek et al., 2005), HBV (Doyle et al., 2006; Pagliaccetti
et al., 2010), HIV (Liu et al., 2012), VSV (Diaz-San Segundo et al.,
2011) and West Nile Virus (Doyle et al., 2006); to name a few. Type
III IFNs therefore produce an antiviral cell state and are classiﬁed
as an antiviral protein family.
The type III interferons, or interferon lambda family, arose by
gene duplication and have retained a high degree of identity to
each other. When the two  members with the highest homology
are compared it is evident IL-28B and IL-28A arose from an inver-
sion following a gene duplication event (Donnelly and Kotenko,
2010; Sugiyama et al., 2011). As such the coding region of IL-28B has
98% identity to IL-28A. The high per cent identity between IL-28B
and IL-28A also extends to the regulatory sequence upstream and
downstream of each gene (Donnelly and Kotenko, 2010; Ito et al.,
2011; Reynolds et al., 2012; Sugiyama et al., 2011), where >95%
identity is observed over a 7.3 kb region (Reynolds et al., 2012).Given the high degree of identity between IL-28A and IL-28B, a
series of studies (Ito et al., 2011; Reynolds et al., 2012; Sugiyama
et al., 2011) have questioned the validity of genotyping the sin-
gle nucleotide polymorphism (SNP) rs12979860 on IL-28B. This
nder the CC BY license (http://creativecommons.org/licenses/by/3.0/).
40 B.S. Thomas et al. / Journal of Virological Methods 203 (2014) 39–47
Fig. 1. Alignment of IL-28B rs12979860 on homologous region of IL-28A. ClustalW ver. 2.1 alignment of the positive strand of the Genome Reference Consortium Human
build  37, from the region surrounding IL-28B rs12979860 ampliﬁed in the SNP genotyping assay, as compared to the homologous region on the IL-28A promoter. The gene
inversion event that produced the IL-28B and IL-28A duplication resulted in an inverted orientation, whereby the coding regions of the respective genes are shown as boxes
at  opposite ends of this alignment. The coding region for IL-28B is shown downstream of rs12979860, which is at −3069 bp relative to the start codon, and the equivalent
nucleotide for IL-28A resides at −3755 bp. The SNP rs12979869 can contain a C or a T on the positive strand of the genome, whereas the homologous region on the IL-28A
promoter is not a SNP, and only contains a T nucleotide on the negative strand, at −3755. Positive symbols at the left hand side of the alignment denote which strand in the
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renomic  region the sequence originated from.
ocus contains either a thymidine (T) or a cytosine (C), whereas
he homologous sequence in the promoter of IL-28A is an exact
atch to the T allele (Reynolds et al., 2012), and does not contain a
olymorphism (Fig. 1). In this scenario, it is essential to show that
enotyping assays for rs12979860 are speciﬁc for IL-28B. Other-
ise, the detection of the T nucleotide at −3755 on IL-28A, the locus
omologous to rs12979860, could lead to an under-representation
f the reported C allele frequency of rs12979860.
The most widely utilized TaqMan® SNP genotyping assay for
s12979860 has never been proven to be speciﬁc for IL-28B
Amanzada et al., 2012; Anthony et al., 2012; Cariani et al., 2011;
harlton et al., 2011; de Rueda et al., 2011; Del Campo et al., 2013;
iorina et al., 2012; Firpi et al., 2013; Ito et al., 2011; Lee et al., 2013;
alhotra et al., 2011; Montes-Cano et al., 2010; Pol et al., 2013;
uiz-Extremera et al., 2011; Stattermayer et al., 2011; Stenkvist
t al., 2013; Tajir et al., 2012; Thomas et al., 2009; Tillmann et al.,
010; Urban et al., 2010; van den Berg et al., 2011; Wiegand et al.,
011). The T allele frequency from the original TaqMan® SNP geno-
yping study is in concordance with the allele frequency observed in
 GWAS (Thomas et al., 2009). This is not surprising given that both
ethods rely upon DNA hybridization for SNP detection, therefore
oncordance would be expected, but would not disprove non-
peciﬁc IL-28A binding. Given the issues with these two methods
ome have questioned the allele frequency data for rs12979860
Ito et al., 2011; Reynolds et al., 2012; Sugiyama et al., 2012). Yet,
revious efforts have simply demonstrated concordance between
he results from various genotyping assays (Bensadoun et al., 2011;
iorina et al., 2012; Ito et al., 2011). The current study proves the
ost widely used SNP genotyping assay for rs12979860 is speciﬁc
or rs12979860. To conﬁrm the accuracy of the SNP genotype data
or rs12979860, hereby referred to as IL-28B throughout the text,
 set of validation experiments were undertook for the previously
ublished IL-28B rs12979860 TaqMan® genotyping assay (Fig. 1)
Ito et al., 2011; Thomas et al., 2009). Using an in vitro competi-
ion assay, it was determined the published assay is speciﬁc for
s12979860.2. Materials and methods
2.1. In silico analysis
The 66 bp ampliﬁcation product of the rs12979860 IL-28B SNP
genotyping assay was used to ﬁnd the homologous sequence
upstream of IL-28A using the genomic contig AC01145 (chromo-
some 19:39710258:39848077, human genome build GRCh37.p3).
The homologous sequence was identiﬁed with Serial Cloner ver 2.1
(Serial Basics, France). A multiple alignment was then performed
with ClustalW ver. 2.1 (Fig. 1). Oligonucleotide design was per-
formed based on the genomic contig AC011445 in Serial Cloner. All
oligonucleotides were synthesized by Integrated DNA Technolo-
gies (IDT, USA) (Supp. Table 1). Oligonucleotides greater than 25 bp
were PAGE puriﬁed.
Thermodynamic calculations of DNA hybridization between
the −3078 primer and either IL-28B or IL-28A were performed
with HYTHER (Watkins and SantaLucia, 2005), and MELTING ver
4.1f and version 4.3 (2013-05-07; 2013-05-08; Dumousseau et al.,
2012; Le Novere, 2001). With each algorithm a melting temper-
ature (Tm) was calculated. The parameters for the calculation of
DNA hybridization thermodynamics in HYTHER were: [primer]
2.5 × 10−7 mol/L, [gDNA] 6.26 × 10−17 mol/L, hybridization temp.
60.0 ◦C, [NaCl] 0.05 mol/L, [Mg2+] 0.0015 mol/L. Calculations both
with and without correction for microchips and single strand fold-
ing were performed with Santalucia, J. Jr corrections. Genomic DNA
was calculated to be at a concentration of 6.26 × 10−17 mol/L (Supp.
Table 2), whereas assumptions of salt and primer concentrations
were made based on common laboratory practice, but the exact
values were not available as commercial buffers and polymerases
were utilized for most of the subsequent in vitro analysis (see below
for details). The parameters for thermodynamic calculation with
MELTING 4.1f were: nearest neighbor parameters set to default,
[salt] 0.05 M,  nucleic acid correction factor at 2, nucleic acid con-
centration in excess 4.0 × 10−9, salt correction factor SantaLucia
1998, force approximative temperature computation set to true,
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se parameters for dangling ends set to true, use parameters for
ismatches set to true. The parameters for thermodynamic cal-
ulation with MELTING 4.3 were: nearest neighbor parameters of
antaLucia 2004, [salt] 0.05 M,  nucleic acid correction factor of 2 or
, nucleic acid concentration in excess 4.0 × 10−9, salt correction
actor Santa-Lucia 1998, force approximative temperature com-
utation, use parameters for dangling ends, use nearest neighbor
arameters for mismatches, use nearest neighbor parameters for
nosines mismatches of SantaLucia et al. 2005. In MELTING, calcu-
ations were not possible between the primer and −3755 of IL-28A
ithout forcing the approximative temperature computation. This
ethod was then used for both calculations for IL-28B and IL-28A.
 summary of the in silico calculated Tm values are found in Supp.
able 2.
.2. In vitro analysis
.2.1. Ethics statement
All donors gave written informed consent before genotyping.
tudy protocols were approved by the Health Research Ethics Board
t the University of Alberta in Edmonton, Alberta, Canada. In the
urrent study a single healthy control was utilized as a positive
ontrol for a C/C genotype at rs12979860.
.2.2. Tm calculation
Tm values for annealing and denaturing were measured using
n ABI 7900HT Fast Real Time PCR system. SYBR green was used as
 detector in reactions containing the −3078 primer (Supp. Table
) and one of the following: (1) a 90 bp oligonucleotide of the
L-28A region homologous to rs12979860 and complimentary to
he −3078 primer, (2) a 90 bp oligonucleotide of the C allele of
s12979860 and complimentary to the −3078 primer, or (3) a 90 bp
ligonucleotide of the T allele of rs12979860 and complimentary to
he −3078 primer. Dissociation curve conditions consisted of 50 ◦C
or 2 min, 95 ◦C for 10 min, 95 ◦C for 15 s, 95 ◦C for 15 s, a 2% ramp
own to 15 ◦C, 15 ◦C was maintained for 3 min, followed by a 2%
amp up to 95 ◦C, and ﬁnally a maintenance of 95 ◦C for 15 s. The ﬁrst
hree steps in this program are identical to the start of quantitative
eal-time PCR. These cycle conditions were used for three types of
eaction: (1) SYBR in a PCR buffer lacking Taq, or (2) BioRad IQ SYBR
upermix (BioRad, USA), or (3) Life Technologies Power SYBR Green
CR Master Mix  (Life Technologies, USA). Reactions 2 and 3 con-
ained SYBR and a DNA polymerase. Reaction 1, the PCR buffer that
id not contain Taq, was prepared in a 10 mL  volume and consisted
f: 4 mL  of 10X Invitrogen PCR buffer, 2.4 mL  of 50 mM MgCl2,
0 L of each 100 mM dNTP (Invitrogen, USA), 200 L of tween-20,
nd 2 mL  of glycerol. In each 20 L reaction for the non-Taq reac-
ions, reaction 1, 10.8 L of non-Taq PCR buffer was  added, 0.2 L
f 10,000× SYBR (Molecular Probes, USA), a 90 bp oligonucleotide
emplate was added at 5 pmol or 10 pmol, and an equal amount of
he −3078 primer. The volume was increased to 20 L with ddH2O.
or reactions 2 and 3, those containing a polymerase, the master
ix  buffers were added at 1/2 of the 20 L volume, and 5 pmol or
0 pmol of template and primer were combined, the volume was
ncreased to 20 L with ddH2O. For the annealing and denaturing
m calculation with BioRad IQ SYBR supermix (BioRad, USA) an
dditional concentration of a 20 pmol 90 bp oligonucleotide tem-
late along with an equivalent amount of the −3078 primer was
nvestigated. Dissociation curves were plotted in ver. 2.3 of the SDS
oftware (ABI/Life Technologies, USA), and the Tm was determined
s the highest point of the ﬁrst derivative of the denaturing melt
urve, or the lowest value of the ﬁrst derivative in the annealing
elt curve..2.3. Competition assay
The SNP genotyping assay was purchased from Applied Biosys-
ems/Life Technologies, USA. Genomic DNA was prepared fromcal Methods 203 (2014) 39–47 41
whole blood.(Higuchi, 1989; McCluskie and Weeratna, 2001) DNA
was genotyped using an ABI 7900HT Fast Real Time PCR system
as recommended for a TaqMan® SNP genotyping assay (ABI/Life
Technologies, USA). Brieﬂy, 1.25 L of a 20× combined primers
and probes mix  (ABI/Life Technologies, USA), were added to 12.5 L
of 2× TaqMan® Universal PCR master mix  (ABI/Life technologies,
USA), in a 25 L ﬁnal volume of DNAse/RNAse-free water (Invitro-
gen/Life Technologies, USA) and template. Template was  added as
described below. The cycle conditions were: 50 ◦C for 2 min, 95 ◦C
for 10 min, 95 ◦C for 15 s, and 60 ◦C for 1 min. The last two  steps
were repeated 40 times. Automatic call decisions were made with
the SDS software version 2.3 (ABI/Life Technologies, USA). Allelic
discrimination plots were produced in GraphPad Prism ver. 5.0d
(GraphPad Software, USA), and labeled in Photoshop CS6 (Adobe,
USA). For each allelic discrimination experiment, every sample was
run in duplicate. A positive control was performed for each run, and
these consisted of an oligo for the T allele of rs12979860 (marked
T+ in the text and ﬁgures) or the C allele of rs12979860 (marked C+
in the text and the ﬁgures). A non-template control was  also run
for each experiment, along with a genomic DNA  sample from an
individual previously genotyped to be C/C at rs12979860. Allelic
discrimination was performed with genomic DNA in competition
with a synthetic oligo for −3755 of IL-28A (Fig. 2). The IL-28A
oligonucleotide was  a perfect match for the genome assemblies of
this region, the Genome Reference Consortium human build 37, and
2 alternate chromosome 19 assemblies. With this oligonucleotide
a dilution series was then performed (Fig. 2, Supp. Table 2), in
order to determine the ampliﬁcation dose response curves when
performed alone, or in competition with genomic DNA (gDNA)
from an individual homozygous for C at rs12979860. The genomic
DNA was at a concentration of 6.26 × 10−17 M (244.8 pg/L), which
is 942 molecules (Supp. Table 2), and the corresponding IL-28A
oligonucleotide was  added at concentration multiples of 10-fold
above and below this concentration. For all calculations (Supp.
Table 2), an assumption was made that the average length of a male
and female duplex human genome is 6.35 × 109 bp (Lander et al.,
2001), and the average molecular weight of a nucleotide pair is
615.8771 g/mol at physiologic pH (Dolezel et al., 2003). Allelic dis-
crimination was also performed in a fully synthetic scenario using
only oligonucleotides (Fig. 3).
2.2.4. Primer efﬁciency
The −3078 primer efﬁciency was  determined with the dilution
series in the synthetic oligonucleotide discrimination plot of Fig. 3A,
where the PCR was  performed with TaqMan® Universal PCR mas-
ter mix  (ABI/Life Technologies, USA). Threshold crossing values, Ct,
were determined with the RQ manager software ver. 2.4 (Life Tech-
nologies, USA). Change in Ct between dilutions, deﬁned as the slope,
was calculated for each 1/10 dilution, and the average of this was
used to calculate the fold increase per cycle and the efﬁciency as
previously described (Pfafﬂ, 2001).
Fold increase/cycle = 10(−1/slope) (1)
Efﬁciency = [Fold increase/cycle]  − 1 (2)
2.2.5. Off-target ampliﬁcation model
Non-linear regression of total ﬂuorescence was  performed with
R ver 3.0.0 (R-project.org) using Rstudio ver. 0.97.449. FAM and
VIC ﬂuorescence were imported into Rstudio and converted to per-
cent ﬂuorescence; the data values occupied a range from 0 to 1.
Fluorescence was  then ﬁt to the relative amount of off-target tem-
plate in each reaction, expressed as the log10 of the numbers of
molecules as compared to the on-target template DNA. A type 2
Weibull cumulative distribution model (Weibull, 1951) was used
in the dose response curve package {drc} of R (Ritz and Streibig,
2005). Non-linear regression with the 2 parameter type 2 Weibull
42 B.S. Thomas et al. / Journal of Virological Methods 203 (2014) 39–47
Fig. 2. Allelic discrimination of genomic rs12979860 and a synthetic oligonucleotide of the homologous region of IL-28A. (A) Allelic discrimination plot. Points in blue have
been  determined to be the T allele by the automatic call algorithm (SDS v2.3). Points in red have been determined to be the C allele by the automatic call algorithm (SDS v2.3).
Any  reactions that are heterozygous would be green, and all reactions undetermined by the automatic call algorithm (SDS v2.3) are black. A 90 bp oligonucleotide based
on  −3755 of the IL-28A genomic region are labeled × along with the molar concentration. Reactions denoted by open circles, ©,  are the competition experiment samples.
These  were run from a patient with a C/C genotype at rs12979860 at a copy number of 942 molecules (6.26 × 10−17 M),  in competition with IL-28A at the labeled number of
molecules. The same patient’s genomic DNA was  assayed alone (C/C gDNA), with no IL-28A oligonucleotide, and is denoted by , and is labeled C/C 942 molecules, this reaction
had  a copy number of 942 molecules. A non-template control was  performed where no template was added to the reaction, but the SNP genotyping assay was performed,
denoted with an open square, , labeled NTC. Two positive controls reactions were performed, one duplicate set with an oligonucleotide for the C allele of rs12979860, shown
by  , labeled C+, and one duplicate set of an oligonucleotide of the T allele of rs12979860, shown by , and labeled T+. The averages of two replicates are plotted against the
normalized, Rn, FAM ﬂuorescence (SNPT allele), and the normalized, Rn, VIC ﬂuorescence (SNP C allele). (B–G) Ampliﬁcation plots of the allelic discrimination samples. (B–D)
Ampliﬁcation plots of the T allele based on ﬂuorescent FAM release of the TaqMan probe for the T allele. (B) Ampliﬁcation of T allele in control samples: a, T+; b, C/C gDNA; c, C+;
d,  non-template control. (C) Ampliﬁcation of T allele from IL-28A alone, a, IL-28A at 9.42 × 107 molecules; b, IL-28A at 9.42 × 106 molecules; c, IL-28A at 9.42 × 105 molecules;
d,  IL-28A at 9.42 × 104 molecules; e, IL-28A at 9.42 × 103 molecules; f, IL-28A at 942 molecules; g, IL-28A at 94.2 molecules; h, IL-28A at 9.42 molecules. (D) Ampliﬁcation
plot  of T allele in the competition assay: a, C/C gDNA with IL-28A at 9.42 × 107 molecules; b, C/C gDNA with IL-28A at 9.42 × 106 molecules; c, C/C gDNA with IL-28A at
9.42  × 105 molecules; d, C/C gDNA with IL-28A at 9.42 × 104 molecules; e, C/C gDNA with IL-28A at 9.42 × 103 molecules; f–h, C/C gDNA with IL-28A from 942 molecules
down  to 9.42 molecules. (E–G) Ampliﬁcation plots of C allele based on ﬂuorescent VIC release of the TaqMan probe for the C allele. (E) Ampliﬁcation of the C allele in control
samples: a, C+; b, C/C gDNA; c, T+; d, non-template control. (F) Ampliﬁcation of C allele from IL-28A alone, a–h, IL-28A at all copy numbers from 9.42 × 107 molecules to
9.42  molecules. (G) Ampliﬁcation plot of C allele in competition assay: a, C/C gDNA with IL-28A at 9.42 × 107 molecules; b, C/C gDNA with IL-28A at 9.42 × 106 molecules; c,
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a/C  gDNA with IL-28A at 9.42 × 10 molecules; d, C/C gDNA with IL-28A at 9.42 × 10
anels  B–G Rn is plotted against cycle number, where Rn is the baseline adjusted n
unction was chosen, equation three (3), as it produced the lowest
esiduals of the models, and has been used extensively in modeling
opulations. The complete source ﬁle of the R analysis is available
n the Supp. Methods Files 1 and 2, and Supp. Data File 2. As the
ositive control T SNP oligo produced no VIC ﬂuorescence in each
xperiment, it is proposed that 1/2 the maximum VIC ﬂuorescence
n a given dilution series will be an equilibrium point between a
/C genotype and a T/T genotype. In order to calculate the concen-
ration of off-target molecules that produce 1/2 the maximum VIC
uorescence, or the half maximum positive value, KHPV, see Supp.
ethods 1 and 2, and Fig. 3C.
Weibull (type 2) 2 parameter function:
 (x) = 1 − exp(−exp(b(log(x) − log(e)))) (3)
 = shape parameter; b = scale parameter.
. Results
.1. In silico analysis: melting temperature calculations produce
ivergent results.1.1. Multiple alignment
In order to determine if the rs12979860 SNP genotyping
ssay would detect the homologous region of IL-28A, a multipleecules; e–h, C/C gDNA with IL-28A from 9.42 × 10 molecules to 9.42 molecules. In
ized ﬂuorescence.
alignment was  performed (Fig. 1), as these loci are known to have
>95% identity (Reynolds et al., 2012). It was  discovered that the
66 bp product ampliﬁed from rs12979860 in the IL-28B locus,
differed by only three nucleotides when compared to the 66 bp
homologous region in the IL-28A locus, −3755 bp from IL-28A.
These 3 base pairs exclude the difference observed at rs12979860 or
−3755. As a consequence, the −3078 primer and the C allele probe
are the only members of this assay that have mismatched binding
partners on the homologous region of IL-28A (Fig. 1). This explains
why errors have been documented when direct sequencing of the
interferon lambda family was performed (Ito et al., 2011). Given
this result, amplicon length will not distinguish between the two
templates; rs12979860 of IL-28B, and −3755 of IL-28A.
3.1.2. DNA hybridization thermodynamics
To determine the consequences that three mismatched bases
have on the hybridization of the −3078 primer to IL-28A, DNA:DNA
hybridization calculations between the −3078 primer and either
IL-28B or IL-28A were performed with MELTING and HYTHER (Le
Novere, 2001; Watkins and SantaLucia, 2005). Both algorithms rely
on nearest neighbor predictions of thermodynamic energies to
calculate the melting temperature (Tm) of a two molecule DNA
hybridization. For this analysis melting temperature was used
to determine how strongly the interaction between the −3078
B.S. Thomas et al. / Journal of Virological Methods 203 (2014) 39–47 43
Fig. 3. Synthetic oligonucleotide allelic discrimination. (A) Synthetic oligonucleotide allelic discrimination plot of 90 bp oligonucleotides IL-28A, ; T-SNP of IL-28B, ; and
the  C-SNP of IL-28B, . One in ten dilution series of each oligonucleotide was performed beginning with 9.42 × 107 molecules and decreasing to 9.42 molecules. (B) Synthetic
genomic equivalent allelic discrimination plots. With all three 90 bp oligonucleotides, an equivalent molecular concentration of each molecule was recreated as would occur
for  genomic DNA. For each reaction 2 copies of the IL-28A oligonucleotide was added to a homozygous or heterozygous mixture of the C-SNP or T-SNP oligonucleotides. For
this  experiment a 1/2 dilution series was performed beginning at 1884 genomic equivalent copies down to 14.71895 molecules. , synthetic T/T gDNA contained two  copies
of  IL-28A, and two  copies of T-SNP. ×, synthetic C/T gDNA contained two  copies of IL-28A, one copy of C-SNP, and one copy of T-SNP. ©,  synthetic C/C gDNA contained two
copies  of IL-28A, and two copies of C-SNP. (C–E) Synthetic competitive binding assay. The synthetic equivalent of a C/C genomic DNA (C), synthetic equivalent of C/T genomic
DNA  (D), and synthetic equivalent of T/T genomic DNA (E), were added to reactions at 942 genomic equivalent molecules in competition with the IL-28A oligonucleotide at the
marked concentrations. For this assay all reactions at 2 copies of IL-28A, contained 1884 molecules, in order to produce the synthetic genomic equivalent of 942 molecules, but
this  was then supplemented with 9.42 molecules of IL-28A for the lowest concentration in the competition assay and this increased by 10 for each reaction up to a maximum
of  9.42 × 107 molecules. The automatic call algorithm was used for these plots and the result is shown with blue, red or green points, for T/T, C/C and C/T, respectively. In C, ©
are  the synthetic C/C genotype competition reactions. For D, × are the synthetic C/T genotype competition reactions, and in E, , are the synthetic T/T genotype competition
reactions. For each plot in C–E, a non-template control, no DNA, is shown by , a positive control for the T SNP (T+) was added, , a positive control for the C SNP (C+) was
performed, , and a control reaction of patient DNA with a C/C genotype at 942 molecules was performed (C/C 942 molecules), denoted by . The average of two  replicates
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2re  plotted against the normalized, Rn, FAM ﬂuorescence (SNP T allele), and the nor
rimer is to IL-28B or IL-28A; a higher melting temperature being
he result of stronger hydrogen bonding between the hybrid
olecule.
Using MELTING, ver. 4.1f or 4.3, a melting temperature of
7.08 ◦C was calculated for the annealing of the −3078 primer
o either IL-28B or IL-28A, however it was necessary to force an
pproximate temperature computation in order to determine the
elting temperature of the −3078 bp primer to IL-28A due to the
resence of mismatches. The result was the same with either ver-
ion of MELTING, and it did not vary as a result of including a nucleic
cid correction factor. When the IL-28B calculation was  not set to
orce the approximate temperature computation, the result was
 melting temperature of 57.58 ◦C, or a half-degree increase from
hat of IL-28A. In contrast, HYTHER produced very different melt-
ng temperatures for hybridization of the −3078 primer to either
L-28B or IL-28A. When the genomic concentration of IL-28B, was
et to 6.26 × 10−17 mol/L (Supp. Table 2 and Supp. Data 1), and the
oncentration of the −3078 primer was set to 2.5 × 10−7 mol/L, melting temperature of 55.0 ◦C was calculated. Whereas at an
dentical concentration of IL-28A and the −3078 primer, a melting
emperature of 32.2 ◦C was calculated, 22.8 ◦C lower than for IL-
8B, suggesting a low likelihood of hybridization between IL-28Aed, Rn, VIC ﬂuorescence (SNPC allele).
and the −3078 bp primer. Even when the concentration of IL-28A
was set to 6.26 × 10−15 mol/L, 100 times higher, no increase in melt-
ing temperature was observed (Supp. Data 1). In the situation of
an extreme overabundance of IL-28A, when the concentration of
IL-28A was  set to 6.26 × 10−7 mol/L, 1010 times excess, the melt-
ing temperature only increased by 1.3–33.5 ◦C. It was only when
IL-28A reaches a concentration of 6.26 × 10−2 mol/L that a Tm of
57.8 ◦C was  observed; a melting temperature above that of IL-28B
at 6.26 × 10−17 mol/L.
Given the large discrepancy between MELTING and HYTHER’s
values, the speciﬁcity of this assay was  questioned. In addition,
these calculations are dependent on the concentrations of mono-
valent and divalent cations in the PCR solution, which given the
propriety nature of current polymerases and their supplied buffers,
have become increasingly difﬁcult to determine. Furthermore, the
IL-28B rs12979860 TaqMan® genotyping assay is a dynamic system
with DNA polymerase and 12 species of DNA molecules binding,
whereas the thermodynamic calculations performed only model
a two  molecule DNA dimerization. Given these potential issues,
combined with the large discrepancy between the melting tem-
peratures of IL-28A between algorithms, an empirical method to
validate the SNP assay was pursued.
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.2. In vitro analysis: allelic discrimination
.2.1. Oligonucleotide dissociation curves
To determine the annealing temperatures of the −3078 primer
o the IL-28B and IL-28A templates, annealing and melting tem-
eratures were measured using dissociation curves (Supp. Table
). At primer and template concentrations of 10 pmol, it was deter-
ined the primer anneals to 50% of the template at 70.00 ± 0.92 ◦C,
9.87 ± 0.35 ◦C, or 53.17 ± 0.87 ◦C, for the C allele of IL-28B, the T
llele of IL-28B, or IL-28A, respectively. When dissociation curves
ere performed with one of the PCR buffers that contain a DNA
olymerase, the 10 pmol reactions produced annealing tempera-
ures of 75.47 ± 0.12 ◦C, 75.50 ± 0.12 ◦C, or 62.87 ± 0.67 ◦C, for the
 allele of IL-28B, the T allele of IL-28B, or IL-28A, respectively.
nterestingly, the annealing temperature of the −3078 primer to
he off-target IL-28A template was above 60 ◦C, the annealing
emperature used for genotyping in the TaqMan® based assay
ABI/Life Technologies, USA). This experiment was  then repeated
ith Power SYBR Green PCR Master Mix  (ABI/Life Technologies,
SA), a buffer also containing a DNA polymerase, and the 10 pmol of
rimer and template had annealing temperatures of 68.6 ± 0.10 ◦C,
8.17 ± 0.07 ◦C, or 54.50 ± 0.17 ◦C for the −3078 primer with the
 allele template of IL-28B, the T allele of IL-28B, or the IL-28A
ligonucleotide (Supp. Table 3). Buffer components are therefore
ritical for minimizing off-target ampliﬁcation.
.2.2. Genomic allele discrimination
In order to determine if the rs12979860 SNP genotyping assay
Thomas et al., 2009) ampliﬁes and only detects IL-28B, a compe-
ition experiment was designed where an oligonucleotide for the
omologous region of IL-28A (Supp. Table 1) was spiked into a reac-
ion with genomic DNA (Fig. 2, Supp. Table 2). The ampliﬁcation
inetics of the competition reaction together with the total amount
f DNA produced, were measured with TaqMan® probes for the T
nd C alleles (Figs. 1 and 2, Supp. Tables 1 and 2). It was observed
hat even with 100 times more of the IL-28A competitor present
han the genomic DNA from a C/C individual, the sample was read
s being a C/C genotype (Fig. 2, Supp. Table 2). When 1000 times
ore IL-28A was added to the reaction the automatic call algo-
ithm could not determine the genotype (Fig. 2A), but the FAM
nd VIC ﬂuorescent intensities after ampliﬁcation mimicked that
f a heterozygous C/T individual (Fig. 2A, D and G). With 10,000-
old more IL-28A present in a reaction, or greater, the automatic
all algorithm determined these samples to be homozygous T/T at
s12979860 (Fig. 2A, D and G). Fortunately, the minor groove bind-
ng TaqMan® probes for the C allele and the T alleles are speciﬁc in
he current assay (Fig. 2B, C, E and F). This in vitro competition assay
hows the SNP genotyping assay for IL-28B is speciﬁc when a single
enome is present. However, 3 nucleotide mismatches between a
9 bp primer and its template, can provide an effective template for
mpliﬁcation when an off-target template is present at high con-
entration relative to the desired on-target template. The result
btained was between the two extremes calculated with MELTING
nd HYTHER, whereby one method did not determine a binding
ifference, and the other determined binding to be highly unlikely.
.2.3. Allelic discrimination with a synthetic genome
In order to determine if the ampliﬁcation dose response curves
ere the result of preferential binding of a primer to genomic
NA or to a short oligonucleotide, a synthetic oligonucleotide was
sed to mimic  genomic DNA in a competition assay. This was
one to prove the observed speciﬁcity in a system with equivalent
olecules. A separate dilution series of each 90 bp ssDNA oligo were
erformed on: (1) the C allele of IL-28B, or (2) the T allele of IL-28B,
r (3) IL-28A (Fig. 3A). Ampliﬁcation of the T allele of IL-28B was
ore efﬁcient than IL-28A, which has 3 mismatched base pairs. Ascal Methods 203 (2014) 39–47
a result the T allele of IL-28B produced more FAM ﬂuorescence than
IL-28A at each dilution. The efﬁciency of the PCR ampliﬁcation for
the −3078 primer with the C or T SNP template of IL-28B were
98.91 ± 0.04% and 97.10 ± 0.06%, respectively, whereas the efﬁ-
ciency for IL-28A was  96.67 ± 0.02% (Supp. Table 2E). The amount
of ampliﬁcation was similar to that observed for the genomic DNA
reactions, whereby increasing amounts of template caused increas-
ing amounts of ﬂuorescence extending out from the origin (y = 0 and
x = 0). The question then arose whether a synthetic genomic reac-
tion could be produced whereby a reaction would contain either
of three genotypes: (1) C/C at IL-28B and T/T at IL-28A, (2) C/T at
IL-28B and T/T at IL-28A, or (3) T/T at IL-28B and T/T at IL-28A. It
was possible to produce ampliﬁcation with an oligonucleotide act-
ing as a template in lieu of genomic DNA (Fig. 3B). In a synthetic
C/C IL-28B genotype, increasing amounts of template extended out
from the origin producing greater amounts of VIC ﬂuorescence. In
contrast, increasing amounts of a synthetic IL-28B T/T genotype
produced increasing amounts of FAM ﬂuorescence. Finally a syn-
thetic C/T genome extended out diagonally between the X and Y
axes, as both VIC and FAM ﬂuorescence increased with increasing
amounts of template.
Finally, a competition experiment was  performed with the
allelic discrimination assay using a synthetic genome, by increas-
ing amounts of the −3755 IL-28A oligonucleotide (Fig. 3C–E). It
was found that even with 11 times more molecules of the IL-28A
oligonucleotide present, the automatic call algorithm predicts the
synthetic C/C genotype to be homozygous for the major allele, a
C/C genotype (Fig. 3C), or a synthetic C/T genotype is predicted to
be a heterozygous genotype, a C/T genotype (Fig. 3D). It was only
when 101 times more IL-28A was present that signiﬁcant amounts
of FAM ﬂuorescence were produced, and the genotype prediction
became T/T. In summary, the results of the genomic competition
experiment were in agreement with the synthetic genomic com-
petition experiment, and there was  no preferential ampliﬁcation of
the oligonucleotides over genomic DNA. Ampliﬁcation was  speciﬁc
for rs12979860 in a genomic DNA sample, when an equal concen-
tration of −3755 of IL-28A was present. It was only when −3755
of IL-28A was present at 56–101 times greater than the amount
of rs12979860 that signiﬁcant amounts of FAM ﬂuorescence were
produced, and the genotype of rs12979860 was  falsely inﬂuenced
by off-target ampliﬁcation of the homologous region on IL-28A.
Non-linear regression was performed on the total ﬂuorescent
signals, in order to calculate the exact concentration of IL-28A tem-
plate needed to produce 1/2 the maximum VIC ﬂuorescence. In
the present study it was  shown that 101 or 56 times more IL-
28A molecules than IL-28B molecules, caused the automatic call
algorithm to produce T/T genotypes; these were the samples that
produced the values in the middle of the dose response curves for
total FAM and VIC ﬂuorescence (Supp. Fig. 1B). Using non-linear
regression on the dose response curve, the exact 1/2 max  VIC ﬂuo-
rescence was calculated, herein called KHPV. KHPV was  found to be
15.75 ± 0.0721 (Supp. Fig. 1C), a point below the observed ﬂuores-
cent value measured with 56-fold excess IL-28A.
4. Discussion
Given the interest in understanding the impact of IL-28B on HCV
infection, and more generally its role in an antiviral response, it was
critical to accurately genotype the alleles present at rs12979860.
Accurate genotyping of rs12979860 is complicated by the fact that
IL-28B and IL-28A are highly conserved (Donnelly and Kotenko,
2010; Ito et al., 2011; Reynolds et al., 2012; Sugiyama et al., 2011).
It was necessary to show empirically one of the most widely used
assays in this ﬁeld was speciﬁc for rs12979860, as in silico pre-
dictions for the speciﬁcity of these primers were inconclusive,
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nd there was no published proof. The annealing temperature
as found to vary widely with the PCR buffer utilized in mea-
uring the Tm,  as the −3078 primer binding to IL-28A was found
o be 62.87 ± 0.67 ◦C with IQ SYBR Supermix (BioRad, USA), and
4.50 ± 0.17 ◦C with Power SYBR Green PCR Master Mix (Life Tech-
ologies, USA). Given this discrepancy the ampliﬁcation of the
ff-target template in a competition assay was investigated. With
n in vitro template competition assay, it was  found the −3078
rimer can seed the ampliﬁcation of an off-target IL-28A sequence,
ven with 3 nucleotide mismatches, but the −3078 primer was
5.75 ± 0.0721 times more efﬁcient for priming ampliﬁcation from
L-28B. Therefore, at biological concentrations, where rs12979860
nd −3755 bp of IL-28A are at identical copy number, the described
NP genotyping assay was speciﬁc. The conclusion of this study
as that the results of all studies performed with the described
s12979860 SNP genotyping assay are speciﬁc for IL-28B and all
enotyping results are valid for rs12979860 (Amanzada et al., 2012;
nthony et al., 2012; Cariani et al., 2011; Charlton et al., 2011; de
ueda et al., 2011; Del Campo et al., 2013; Fiorina et al., 2012; Firpi
t al., 2013; Ito et al., 2011; Lee et al., 2013; Malhotra et al., 2011;
ontes-Cano et al., 2010; Pol et al., 2013; Ruiz-Extremera et al.,
011; Stattermayer et al., 2011; Stenkvist et al., 2013; Tajir et al.,
012; Thomas et al., 2009; Tillmann et al., 2010; Urban et al., 2010;
an den Berg et al., 2011; Wiegand et al., 2011). In addition, the
escribed competition assay may  be useful to predict the speciﬁcity
f other primers, and could provide insight to make the current DNA
inding prediction methods more precise at calculating hybridiza-
ion.
In silico DNA:DNA hybridization algorithms have become an
nvaluable tool in molecular biology. Unfortunately, they are only
redictions and do not account for many parameters that may
hange the outcome of hybridizations experimentally observed. In
ilico the −3078 primer binding to rs12979860 of IL-28B was  calcu-
ated to have a Tm of 57.08 ◦C or 57.58 ◦C with MELTING, and 65.2 ◦C
r 55.0 ◦C with HYTHER, depending on the parameters utilized.
hen the homologous region in IL-28A was entered into these
alculations with the −3078 primer, vastly different Tms  were pro-
uced (Supp. Data 1). In vitro the Tms  varied from 62.87 ± 0.67 ◦C,
sing BioRad IQ SYBR supermix (BioRad, USA), to 53.17 ± 0.87 ◦C,
sing SYBR in a PCR buffer lacking Taq (Supp. Table 3). Yet when
n in vitro competition assay was performed the PCR ampliﬁca-
ion of the IL-28B template was 15.75 ± 0.0721 times better than
L-28A (Figs. 2 and 3), as KHPV is a measure of the relative ampli-
cation. Notably, nearest neighbor calculations have difﬁculties
n determining the thermodynamic contribution that the location
f a mismatch along a target sequence has on the melting tem-
erature, and these become even more error prone with multiple
ismatches. As DNA is a polymer, binding is not an all or none
vent, and instead it can occur along the polymer much like a zip-
er closing. In fact this ‘zip-up’ model has been well documented.
ecently it has been shown that only 7 contiguous base pairs
re critical in the annealing kinetics, Kon (Cisse et al., 2012). One
ould imagine a polymerase stabilizing a 7 bp touchdown on the
′ end, thereby allowing for mismatched annealing further along
 primer. This may  account for the observed KHPV values, given
hat the observed Tm’s were inconclusive at predicting hybridiza-
ion leading to ampliﬁcation based on the dissociation curves. In
m calculations this can be referred to as dangling ends. Unfortu-
ately once a dangling end is setup, whereby one molecule on a
imer is shortened, the Tm decreases drastically, yet in practice
hese hybridizations do occur. In recombination based molecular
loning, such as recombineering and InFusion®, or SOEing/Fusion
CR, or site directed mutagenesis, or even synthetic biology, it is
pparent that even though a 40–60 oligomer has a Tm of 90 ◦C, one
an perform a PCR using the Tm of only 1 side of the primer. Pos-
ibly more so than proteins, DNA can bind partially and supportcal Methods 203 (2014) 39–47 45
interactions at temperatures one would not predict possible based
on in silico melting temperatures; most likely due to the ability of
the polymer or the polymerase to partially stabilize interactions.
A better method of calculating off-target effects may  be the cal-
culation of the equilibrium point, KHPV. In the present study, the
off-target ampliﬁcation was  modeled and KHPV was  calculated for
the synthetic genotype competition experiments (Fig. 3C–E, Supp.
Fig. 1). As each PCR reaction begins, the off-target ampliﬁcation con-
tains mismatches, but as the PCR reactions proceed, the off-target
products are perfectly matched to the −3078 bp primer (Supp. Data
1). In the present experiment, KHPV was  therefore indicative of the
starting concentration of the off-target template that will result in
a genotype being measured that was between the IL-28A off-target
and the rs1297860 IL-28B SNP (Supp. Fig. 1A). Therefore, the calcu-
lated KHPV is the concentration of the IL-28A off-target template at
which the allelic discrimination algorithm would report a C/C geno-
type sample as a C/T genotype, or would result in an undetermined
genotype; as it is between the maximum VIC ﬂuorescence and a
control oligonucleotide that contains the T allele of rs12979860
from IL-28B.
5. Conclusions
In summary, DNA is an interesting molecule with the properties
of a polymer that is both the substrate and product of polymerase
reactions. As such the binding dynamics and equilibrium status of
these molecules can be modeled using dose response curves. In the
current study, the half maximum positive value, or KHPV, of the off-
target template in question was  found to be 15.75 ± 0.0721-fold
more than the concentration of the on-target C/C at rs12979860,
in the synthetic C/C genomic DNA experiments. Therefore this off-
target value, represented as the relative fold increase of molecules,
is the point at which the ﬂuorescence of the off-target products
change the clustering of points from the on-target template to the
off-target template (Supp. Fig. 1). With this method the speciﬁcity
of the described TaqMan® SNP genotyping assay for rs12979860
of IL-28B in genomic samples was proven. In vitro this rs12979860
TaqMan® SNP assay becomes problematic only when the homol-
ogous region of IL-28A exceeds the concentration of rs12979860
by 15.75 ± 0.0721 for a C/C genotype. It is believed this validation
method may be of interest to those performing SNP genotyping
on precious clinical samples, as no micro calorimeter is needed for
the validation, and this technique is exquisitely sensitive for mea-
suring these interactions. In contrast, a micro-calorimeter requires
very high amounts of nucleotides, in order to calculate the KD of
DNA hybridization. The added beneﬁt of the described method is
that the same machine running the SNP genotyping assay, is suf-
ﬁcient to calculate KHPV. In conclusion, the previously published
TaqMan® SNP genotype assay for rs12979860 of IL-28B is proven
to be speciﬁc for IL-28B and no off-target ampliﬁcation of IL-28A is
observed in genomic DNA samples.
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